A prognostic factor index for overall survival in patients receiving first-line chemotherapy for HER2-negative advanced breast cancer: an analysis of the ATHENA trial.
Fiche publication
Date publication
octobre 2014
Journal
Breast (Edinburgh, Scotland)
Auteurs
Membres identifiés du Cancéropôle Est :
Pr PIVOT Xavier
Tous les auteurs :
Llombart-Cussac A, Pivot X, Biganzoli L, Cortes-Funes H, Pritchard KI, Pierga JY, Smith I, Thomssen C, Srock S, Sampayo M, Cortes J
Lien Pubmed
Résumé
Evidence-based definitions of 'poor-prognosis' or 'aggressive' advanced breast cancer are lacking.
Mots clés
Adult, Aged, Aged, 80 and over, Antibodies, Monoclonal, Humanized, administration & dosage, Antineoplastic Agents, administration & dosage, Antineoplastic Combined Chemotherapy Protocols, therapeutic use, Bevacizumab, Breast Neoplasms, drug therapy, Decision Support Techniques, Drug Administration Schedule, Female, Humans, Middle Aged, Prognosis, Receptor, ErbB-2, metabolism, Risk Assessment, Risk Factors, Survival Rate, Taxoids, administration & dosage
Référence
Breast. 2014 Oct;23(5):656-62